Fermenta Biotech has informed that the Board of Directors of the Company, at its meeting held today on December 10, 2025, has approved capacity addition requiring investment of up to Rs 110 crores at its existing facility in Dahej, Gujarat, for production of Plant based Vitamin D3, Vitamin D3 derivatives, and Green Chemistry Enzymes to be phased across FY26 and FY27. The information required as per Listing Regulations read with SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 (‘Master Circular’) is enclosed as Annexure A. Press release explaining the rationale and other information related to capacity addition is also enclosed. The Board meeting commenced at 11:30 am (IST) and concluded at 2:50 pm (IST).
The above information is a part of company’s filings submitted to BSE.
